Coherus Oncology (CHRS) Operating Margin (2016 - 2025)
Historic Operating Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 383.14%.
- Coherus Oncology's Operating Margin rose 3910800.0% to 383.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.36%, marking a year-over-year increase of 1691900.0%. This contributed to the annual value of 41.83% for FY2024, which is 371600.0% up from last year.
- As of Q3 2025, Coherus Oncology's Operating Margin stood at 383.14%, which was up 3910800.0% from 443.59% recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Operating Margin registered a high of 17.16% during Q4 2024, and its lowest value of 2937.05% during Q1 2024.
- Its 5-year average for Operating Margin is 353.2%, with a median of 134.62% in 2022.
- As far as peak fluctuations go, Coherus Oncology's Operating Margin tumbled by -27281900bps in 2024, and later soared by 23391400bps in 2025.
- Quarter analysis of 5 years shows Coherus Oncology's Operating Margin stood at 53.91% in 2021, then tumbled by -111bps to 113.54% in 2022, then skyrocketed by 34bps to 75.29% in 2023, then soared by 123bps to 17.16% in 2024, then plummeted by -2333bps to 383.14% in 2025.
- Its Operating Margin stands at 383.14% for Q3 2025, versus 443.59% for Q2 2025 and 597.91% for Q1 2025.